<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986580</url>
  </required_header>
  <id_info>
    <org_study_id>CP-010</org_study_id>
    <nct_id>NCT03986580</nct_id>
  </id_info>
  <brief_title>Study of Lumbar Discectomy With Annular Closure</brief_title>
  <official_title>Prospective Evaluation Of Lumbar Discectomy With Additional Implantation Of An Annular Closure Device In Patients With Large Postsurgical Annular Defects For Prevention Of Lumbar Disc Reherniation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrinsic Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrinsic Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective, single-arm, multicenter study is to assess an annular&#xD;
      closure device when used as an adjunct to a primary lumbar limited discectomy, to limited&#xD;
      discectomy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-arm case series will enroll 75 patients at select US (approximately 8-10) sites.&#xD;
      Patients that are scheduled for a single-level L4-S1 discectomy and who meet the&#xD;
      pre-operative eligibility criteria will be considered for study participation. Patients that&#xD;
      meet all intraoperative criteria will be enrolled into the study and treated with lumbar&#xD;
      discectomy and additional annular closure device implantation. All enrolled subjects will be&#xD;
      followed for at least 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Amount of blood loss measured in ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Intra-operative</time_frame>
    <description>Length of surgery, measured in minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)</time_frame>
    <description>Length of the hospital stay measured in days between hospital admission and hospital discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discharge status</measure>
    <time_frame>Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)</time_frame>
    <description>Evaluation of improvement in motor and sensory neurologic status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg pain severity (0-100 VAS score)</measure>
    <time_frame>Baseline, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Back pain severity (0-100 VAS score)</measure>
    <time_frame>Baseline, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ODI</measure>
    <time_frame>Baseline, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Baseline, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction with surgery procedure</measure>
    <time_frame>1 year</time_frame>
    <description>Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurological assessment</measure>
    <time_frame>Baseline, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as &quot;normal&quot;, &quot;increased&quot;, &quot;absent&quot; and &quot;decreased&quot;) and muscle strength measured 0-5 with &quot;0&quot; representing no evidence of motor strength and &quot;5&quot; representing full resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline, Intra-operative, 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital readmission occurrence</measure>
    <time_frame>Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in incidence of re-admissions to hospital, post treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic reherniation incidence</measure>
    <time_frame>Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reoperation incidence</measure>
    <time_frame>Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in incidence of post-operative reoperation at the index level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Return to work assessment</measure>
    <time_frame>4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline in work status (ability to return to work, with or without reported restrictions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>Baseline, Intra-operative, Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year</time_frame>
    <description>Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Lumbar Disc Herniation</condition>
  <arm_group>
    <arm_group_label>Annular closure device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study; all patients treated with an annular closure device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Annular closure device</intervention_name>
    <description>Annular closure, following limited discectomy procedure at a single LS level between L4 and S1</description>
    <arm_group_label>Annular closure device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years old and skeletally mature (male or female)&#xD;
&#xD;
          2. Subjects with posterior or posterolateral disc herniations at one level between L4 and&#xD;
             S1 with radiographic confirmation of neural compression using MRI. [Note:&#xD;
             Intraoperatively, only patients with an anular defect (post discectomy) between 4mm&#xD;
             and 6mm tall and 6mm and 10mm wide shall qualify.]&#xD;
&#xD;
          3. At least six (6) weeks of failed, conservative treatment prior to surgery, including&#xD;
             physical therapy, use of anti-inflammatory medications at maximum specified dosage&#xD;
             and/or administration of epidural/facet injections.;&#xD;
&#xD;
          4. Minimum posterior disc height of 5mm at the index level.&#xD;
&#xD;
          5. Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60&#xD;
             degrees)&#xD;
&#xD;
          6. Oswestry Questionnaire score of at least 40/100 at baseline.&#xD;
&#xD;
          7. VAS leg pain (one or both legs) of at least 40/100 at baseline.&#xD;
&#xD;
          8. Psychosocially, mentally and physically able to fully comply with the clinical&#xD;
             protocol and willing to adhere to follow-up schedule and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Spondylolisthesis Grade II or higher (25% slip or greater).&#xD;
&#xD;
          2. Subject requires spinal surgery other than a discectomy (with or without laminotomy)&#xD;
             to treat leg/back pain (scar tissue and osteophyte removal is allowed).&#xD;
&#xD;
          3. Subject has back or non-radicular leg pain of unknown etiology.&#xD;
&#xD;
          4. Prior surgery at the index lumbar vertebral level&#xD;
&#xD;
          5. Subject requiring a spine DEXA (i.e., patients with SCORE of â‰¥ 6) with a T Score less&#xD;
             than -2.0 at the index level. For patients with a herniation at L5/S1, the average T&#xD;
             score of L1-L4 shall be used.&#xD;
&#xD;
          6. Subject has clinically compromised vertebral bodies in the lumbosacral region due to&#xD;
             any traumatic, neoplastic, metabolic, or infectious pathology.&#xD;
&#xD;
          7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of&#xD;
             the vertebra or hip&#xD;
&#xD;
          8. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).&#xD;
&#xD;
          9. Any metabolic bone disease.&#xD;
&#xD;
         10. Subject has an active infection either systemic or local.&#xD;
&#xD;
         11. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.&#xD;
&#xD;
         12. Subject has severe arterial insufficiency of the legs or other peripheral vascular&#xD;
             disease. (Screening on physical examination for patients with diminution or absence of&#xD;
             dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation,&#xD;
             then an arterial ultrasound is required with vascular plethysmography. If the absolute&#xD;
             arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is&#xD;
             to be excluded.)&#xD;
&#xD;
         13. Subject has significant peripheral neuropathy, defined as a subject with Type I or&#xD;
             Type II diabetes or similar systemic metabolic condition causing decreased sensation&#xD;
             in a stocking-like or non-radicular and non-dermatomal distribution in the lower&#xD;
             extremities.&#xD;
&#xD;
         14. Subject has insulin-dependent diabetes mellitus.&#xD;
&#xD;
         15. Subject is morbidly obese (defined as a body mass index &gt;40, or weighs more than 100&#xD;
             lbs over ideal body weight).&#xD;
&#xD;
         16. Subject has been diagnosed with active hepatitis, AIDS, or HIV.&#xD;
&#xD;
         17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.&#xD;
&#xD;
         18. Subject has a known allergy to titanium, polyethylene or polyester materials.&#xD;
&#xD;
         19. Any subject that cannot have a baseline MRI taken.&#xD;
&#xD;
         20. Subject is pregnant or interested in becoming pregnant in the next 2 years.&#xD;
&#xD;
         21. Subject has active tuberculosis or has had tuberculosis in the past three (3) years.&#xD;
&#xD;
         22. Subject has a history of active malignancy: A subject with a history of any invasive&#xD;
             malignancy (except non-melanoma skin cancer), unless he/she has been treated with&#xD;
             curative intent and there have been no signs or symptoms of the malignancy for at&#xD;
             least two (2) years.&#xD;
&#xD;
         23. Subject is immunologically suppressed, received steroids &gt;1 month over the past year.&#xD;
&#xD;
         24. Currently taking anticoagulants, other than aspirin, unless the patient can be taken&#xD;
             off the anticoagulant for surgery.&#xD;
&#xD;
         25. Subject has a current chemical/alcohol dependency or significant psychosocial&#xD;
             disturbance.&#xD;
&#xD;
         26. Subject has a life expectancy of less than three (3) years.&#xD;
&#xD;
         27. Subject is currently involved in active spinal litigation.&#xD;
&#xD;
         28. Subject is currently involved in another investigational study.&#xD;
&#xD;
         29. Subject is incarcerated.&#xD;
&#xD;
         30. Any contraindication for MRI (e.g. claustrophobia, contrast allergy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New england Baptist Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC San Diego Health System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist - Lyerly Neurosurgery</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Institute of Western Kentucky</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Spine Institute</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101-4643</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Orthopaedic Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

